- LOGIN
- MemberShip
- 2025-12-26 19:25:59
- Company
- Amgen-CKD ink co-promotion deal on Evenity
- by Nov 16, 2020 06:03am
- CEO Kim Young-joo of Chong Kun Dang (left) and General Manager Noh Sang-kyung of Amgen Korea are photographed after signing an agreement On Nov. 12, Amgen Korea (General Manager Noh Sang-kyung) and Chong Kun Dang (CEO Kim Young-joo) announced they signed a co-promotion agreement on a novel osteoporosis drug Evenity (romososumab) on Nov. 11. The two companies also renewed the Prolia (denosumab) co-promotion deal as well. According to the agreement, Amgen Korea would focus on the Prolia and Evenity sales and marketing in general hospital accounts, whereas Chong Kun Dang would center semi hospital. Their partnership is expected to consolidate the synergy effect between Amgen Korea’s all bone disease related treatment and Chong Kun Dang’s resources within the treatment area. Launched in November in the South Korean market, Prolia is an osteoporosis drug that inhibits bone absorption by targeting receptor activator of nuclear factor-κB ligand (RANKL), which is a key to survival and formation of osteoclasts. Prolia, administered once every six month, has confirmed its efficacy in reducing the risk of vertebral, non-vertebral and hip fracture. And also the drug demonstrated the effect of increasing bone density and bone fracture reduction with extensive clinical data of 10 years, unprecedentedly long for an osteoporosis drug. Evenity is an osteoporosis drug targeting the protein sclerostin that hinders bone formation, and it can be used on patients with high risk in bone fracture. The drug was released in December 2019 in the South Korean market as a first and the only treatment option with a dual effect that increases bone formation and to a lesser extent reduces bone resorption. General Manager Noh Sang-kyung of Amgen Korea stated, “We are exhilarated to extend our partnership with Chong Kun Dang for Amgen’s novel osteoporosis treatment portfolio including Prolia and Evenity to provide the treatment options to patients in South Korea.” CEO Kim Young-joo of Chong Kun Dang commented, “Chong Kun Dang would do its best to benefit even more patients with the innovative treatments by utilizing the company’s excellent sales force and the market presence.”
- Company
- Dong-A ST introduces SHR-1701 in China
- by Chon, Seung-Hyun Nov 16, 2020 06:02am
- Dong-A ST announced on the 11th that it has signed a contract with Jiangsu Hengrui Medicine to introduce the next-generation immune anticancer drug 'SHR-1701' in Korea. With this contract, Dong-A ST has secured the exclusive domestic development and sales rights of fusion protein, which is undergoing phase I and II clinical trials in China by Jiangsu Hengrui Medicine. The down payment is $2.29 million (about ₩2.5 billion). The technical fee (milestone) according to the stage of development is $8.46 million (about ₩9.5 billion). Jiangsu Hengrui Medicine will supply the finished drug to Dong-A ST. Dong-A ST headquartersAccording to the company, SHR-1701 is a fusion protein that suppresses both PD-L1 and TGF-βRII at the same time, and is expected to show anticancer efficacy against various carcinomas. It suppresses immune evasion and metastasis of cancer cells, and suppresses fibrosis of cancer cells in the tumor microenvironment, thereby removing the physical barrier that protects cancer cells from immune cells and therapeutic agents. Currently, TGF-β is known as one of the causes of the low response rate, which is the disadvantage of immuno-anticancer drugs in the mechanism of inhibition of PD-(L)1. Therefore, researches that increase the effectiveness of immuno-anticancer drugs by simultaneously inhibiting PD-(L)1 and TGF-β at home and abroad have been conducted. It is actively in progress. The company said, “SHR-1701 is expected to have improved anti-cancer effect compared to single-dose therapy and combination therapy of PD-L1 inhibitor or TGF-β inhibitor, and it is possible to reduce development cost and secure pharmaceutical price competitiveness compared to combination therapy with one single substance. That's an advantage.” SHR-1701 is currently undergoing phase I and II clinical trials in China for solid cancers such as non-small cell lung cancer, pancreatic cancer, biliary tract cancer, and cervical cancer. Jiangsu Hengrui Medicine, established in 1970, is a Chinese longevity pharmaceutical company with strengths in anticancer drugs, anesthesia, and pain relievers. Last year, it achieved ₩3.9 trillion in sales, and invested ₩620 billion, 16% of its sales, as R&D expenses. An official from Dong-A ST explained, "Through the introduction of this next-generation anti-cancer drug, we have secured competitiveness in the anti-cancer drug pipeline and the domestic anti-cancer drug market at the same time." He said, "Based on close cooperation with Jiangsu Hengrui Medicine, we will strive to help patients suffering from cancer through successful domestic development."
- Company
- GA leads newly appointed at KRPIA and global companies
- by Eo, Yun-Ho Nov 11, 2020 06:10am
- Multinational pharmaceutical companies in South Korea are busy processing a wave of new recruit changes, specifically happening around government affairs jobs. The pharmaceutical industry sources reported many of pharmaceutical companies, as well as Korean Research-based Pharmaceutical Industry Association (KRPIA), have announced a series of personnel news related to their Government Affairs (GA) and Market Access (MA) divisions. On Nov. 5, KRPIA welcomed Senior Manager Kim Minyoung as a successor to Senior Director Sean Kim to oversee MA and healthcare policy relevant tasks. Previously in charge of new drug listing at Amgen Asia Pacific, Senior Manager Kim has rich experience in marketing, GA and MA. Janssen Korea, on the other hand, appointed Senior Manager Kim Yeonhee to lead the MA team as of October, as the former MA Director Lim Kyunghwa was promoted to Janssen Asia-Pacific. Senior Manager Kim joined Janssen in 2000 as sales, and managed marketing and sales in Janssen China and Asia Pacific Region Office. Now she would also cover MA tasks as well. The anticancer drug part at MSD Korea recruited former Executive Director Park Dongjoon at Novartis as a new Senior Director in GA. Formerly affiliated under Daily Pharm as a reporter, Senior Director Park was in charge of government policy at Novartis since 2011. MSD seems to be expanding the anticancer drug business around an immunotherapy Keytruda to consolidate as a more independent sector. On the contrary, Novartis is currently in search of Park’s successor. Former MA Lead Kim Bo Kyung at UCB has apparently moved on to LG Chem as a MA Leader. UCB has not decided who would fill up Kim’s former position. Former MA Executive Director at Eisai Korea, Kim Kyongsun joined IQVIA as a part of Regulatory Affair (RA) division. Accordingly, Eisai is also looking for a new MA lead. A multinational company GA division insider commented, “As the division is an exceptionally specialized area, most of the specialists are highly sought after to take over the job immediately. So the industry frequently experiences a series of recruitment at once. But for GA in particular, some companies reach out to the National Assembly or news media outlet for the job offer.”
- Company
- A study on Korean patients by Nebilet are released
- by Nov 11, 2020 06:08am
- Menarini Korea (CEO Park Hye-young) presented the results of a BENEFIT subgroup study of Nebilet(Nebivolol, β-blocker) at the 53rd Fall International Conference on the Korean Society of Hypertension (Hypertension Seoul 2020). It was revealed on the 9th. The conference, which was held for two days from the 6th to the 7th, was conducted in the form of online streaming to prevent the spread of COVID-19 At this meeting, Seung-ju Cha, a doctor at Hanyang University Hospital, annonunced 'Impact of baseline pulse rate on the efficacy of Nebivolol in a real world clinical study for hypertension patients ', and Jaewon Lee at Hanyang University Hospital, said ‘Efficacy and safety of 2.5mg dose of Nebivolol in hypertension patients in a real world studies in Korea.’ In addition, Professor Sang Ki Cho of Kwangju Christian Hospital served as the chairman, and Professor Hak-Ryung Kim of SNU Boramae Medical Center introduced ‘Approaches to HTN Treatment with β-blockers : Findings from Real World Evidence.’ In addition, Professor Jong-young Lee of Kangbuk Samsung Hospital published the abstract of 'Efficacy and Safety of Nebivolol in the management of hypertension associated with coronary artery disease: BENEFIT-KOREA Research Results', who participated as the first author. Nebivolol is a third-generation β-blocker of hypertension treatment that selectively blocks β-1 receptors, which are mainly distributed in the heart. The advantage is that it produces Nitric oxide to dilate blood vessels, and that there is little risk of side effects of bronchospasm caused by β-2 blockade. Due to its high cardiac selectivity, it is advantageous for patients with high blood pressure with angina pectoris, myocardial infarction, tachyarrhythmia, or fast pulse. Menarini Korea conducted a BENEFIT study in 66 hospitals in Korea from July 2015 to March 2017 in which Nebilet was administered to 3250 adult hypertensive patients to observe the treatment effect for 24 weeks. The research results released on this day are the presentation of analysis results for subgroups as part of the BENEFIT study. Park Hye-young, CEO of Menarini Korea explained, "Nebilet, a third-generation β-blocker, is a product that minimizes side effects such as bradycardia, bronchospasm, and the effects of blood sugar and lipids, which were pointed out as disadvantages of the first-generation β-blockers, and enhances the blood pressure lowering effect." In addition, she said, "We will continue to prove the efficacy and safety of Nebilet through various studies to provide useful treatment options for Korean hypertensive patients."
- Company
- Daewoong,enters phase III of indications for Enavogliflozin
- by Nov 10, 2020 06:05am
- Daewoong (CEO Seung-ho Jeon) announced on the 30th of last month that it had received approval for a phase III clinical trial from the MFDS for the combination therapy of Enavogliflozin, Metformin, and DPP-4 inhibitor, which are being developed as a new drug for diabetes treatment. Enavogliflozin is a new drug for the treatment of SGLT-2 diabetes being developed by Daewoong for the first time among Korean companies. In this phase III, the hypoglycemic effect and safety of the three-drug therapy will be confirmed in 250 patients with type II diabetes who do not sufficiently control blood sugar even if Metformin and a DPP-4 inhibitor are administered together. Clinical trials are conducted in about 20 large hospitals nationwide, including the Catholic University of Bucheon St. Mary's Hospital. As Daewoong is approved for this clinical trial, from Enavogliflozin's monotherapy and combination therapy with Metformin, to three-drug therapy, Enavogliflozin will be used as a treatment for patients whose blood sugar is not controlled even when co-administered with existing diabetes treatments. Daewoong plans to expand its market share by adding indications for Enavogliflozin. In particular, Enavogliflozin was designated as Korea's first rapid review target (Fast Track) drug, allowing the period of new drug approval to be shortened. Daewoong is aiming to be released in Korea in 2023. Seung-Ho Jeon, president of Daewoong said, "Daewoong is making further efforts to expand the indication for Enavogliflozin to help control blood sugar in type II diabetes patients from mild to moderate. Enavogliflozin is also planning to expand its treatment benefits by expanding various indications besides diabetes, as it is expanding into therapeutics.” Enavogliflozin is an SGLT-2 inhibitor that selectively inhibits the SGLT-2 transporter involved in the reabsorption of glucose in the kidneys and directly excretes glucose into the urine. As a result of the phase II study, when compared with placebo alone after 12 weeks of administration in type II diabetic patients, the change in glycated hemoglobin (HbA1c), a major indicator of blood sugar control, decreased by about 0.9% compared to placebo. This is the result of a reduction of more than about 30% compared to the existing SGLT-2 inhibitors that were conducted in Westerners. In addition, the global standard diabetes control target, 'the proportion of patients who reached below 7.0% of glycated hemoglobin' reached a maximum of 61%, and the proportion of patients whose glycated hemoglobin decreased by more than 0.5% compared to before treatment reached a maximum of 72%. As a result, it showed superior blood sugar reduction effect compared to the existing SGLT-2 inhibitor.
- Company
- Covered drugs decreased due to generic drug price system
- by Chon, Seung-Hyun Nov 09, 2020 06:18am
- Number of drugs on the monthly list of health insurance benefits (unit: number, source: the HIRA) The soaring number of medicines covered by health insurance showed a sharp decline. As the number of new generic licenses decreased due to the implementation of the new drug price system, the number of covered drugs decreased in 11 months. According to the HIRA on the 8th, as of November 1, the total number of drugs on the health insurance benefit list was 25,830, down 697 from the previous month's 26, 527. It was only 11 months since December last year that the number of covered drugs has decreased from the previous month. Health insurance-covered drugs have increased for 10 consecutive months from December of last year to October of this year. During this period, the number of covered drugs increased by 3,265 from 23,262 to 26,527. From the end of 2018, the number of covered drugs started to soar. From November 2018 to last month, except for No. 1, there was an increase every month. In November 2018, the number increased from 20,689 to 26,527 in two years. As the number of newly listed drugs decreased, the total number of covered drugs also decreased. From January to August, the total number of drugs registered for new benefits was 3,632. This means that an average of 454 items per month are newly listed on the health insurance benefit list. The previous drug price system was applied to the reimbursed list in May, but 836 items were listed in August. However, the number of new listings has declined sharply from September. In September, the number of newly-listed drugs was 122, a decrease of more than 700 from the previous month, and in October and November, it was only 108 and 60, respectively. The number of drugs listed for new benefits per month (Unit: number, Source: the MOHW) This is a change that emerged from the implementation of the new drug price system. According to the reorganized drug price system, which took effect in July, generic products can maintain the 53.55% upper limit compared to the original drug before the expiration of the patent only when both the direct conduct of the bioequivalence test and the use of the registered drug substance are satisfied. A stepped drug price system has also been introduced, in which the upper limit is lowered as the registration period is delayed. In fact, the government's policy to strengthen generic regulations has led to a surge in new generic licenses by pharmaceutical companies for about two years. In this year, a total of 1,631 generics were licensed until last May. On average, 326 generics per month received new licenses. However, after a sharp decline to 73 cases in June, 70 cases in July and 50 cases in August showed a marked decline. According to the MOHW, the previous drug price system will be applied to products applied for the list in May. Generics, which have been approved since June and applied for the registration, are said to receive low drug prices by applying the new drug price system. This is the background of the sharp decline in the number of new generic licenses from June. The MFDS' attempts to strengthen licensing regulations have contributed to the licensing of a bunch of generics. In recent years, with the recommendation of the Regulatory Reform Committee of the Office for Government Policy Coordination, the strengthening of regulations on the joint bioequivalence test was unsuccessful, but applications for generic licenses increased sharply shortly after the plan to strengthen the biometrics regulation was disclosed earlier last year. In the industry, it is also evaluated that as a result of the intensive approval of generics for pharmaceutical companies in the government's regulatory reinforcement movement, the areas for further entry into the market have significantly decreased. This means that most of the generics that pharmaceutical companies can sell were licensed before the tightening of regulations. From December 2018 to May this year, a total of 5,611 generics were newly entered. On average, 312 generics were released per month.
- Company
- Generics for Lyrica, expanded by 60% in 3 years
- by Kim, Jin-Gu Nov 09, 2020 06:18am
- Lyrica The market for Pregabalin, a pain treatment drug for peripheral neuropathy, has expanded rapidly over the past three years. The amount of outpatient prescriptions from ₩19.8 billion in the third quarter of 2017 increased 61% to ₩32 billion in three years. It is an analysis that the growth of generics after the expiration of the patent has greatly contributed to the market expansion. Pfizer tried to defend generics by releasing new low-dose products and sustained-release formulations, but sales of the original 'Lyrica' are not as good as expected. According to the drug market research institute UBIST on the 4th, the market size of Pregabalin in the third quarter of this year reached 32 billion. It increased by 9% from ₩29.4 billion in the third quarter of last year. It is rapidly expanding since the third quarter of 2017. It is confirmed that it is 61% larger than 3 years ago, compared to ₩19.8 billion in the third quarter of 2017. In particular, the prescription performance of generics increased significantly during this period. Pregabalin's prescription performance increased more than 10 times from ₩1.5 billion in the third quarter of 2017 to ₩15.2 billion in the third quarter of this year. On the other hand, Lyrica decreased 9% from ₩18.3 billion to ₩16.7 billion over the same period. Looking at the quarterly results for the past three years, it appears that prescription performance has been stagnant with approximately ₩16 billion to ₩17 billion. Quarterly prescription performance of Lyrica and generics (Pregabalin) (Unit: ₩100 million, Source: UBIST) Lyrica's patent expiration is the reason why this generic market has expanded rapidly since three years ago. The core of this patent was the indication (application patent). A patent dispute between the original company and the generic company continued over whether generic products could be used for 'treatment of peripheral and central neuropathic pain in adults'. In the dispute that reached the Supreme Court, Pfizer finally won. Generic companies have been releasing products one after another since Lyrica's PMS expired in 2011, but they were unable to achieve satisfactory results due to failure to secure indications. Then, in August 2017, the use patent expired. The prescription performance of generics has grown rapidly from this period. generics for Lyrica, which had produced ₩1 billion in prescriptions until the third quarter of 2017, jumped to ₩4 billion in the fourth quarter of that year. The share of generics in the entire Pregabalin market has also increased from less than 10% to 20%. From 2018, the prescription performance of generics has increased sharply. The generic share in the Pregabalin market exceeded 30% in the second quarter of 2018 and 40% in the third quarter of 2019. In the third quarter of this year, the market share increased to 48%. It is expected that this trend will overtake the original prescription amount as early as in the fourth quarter of this year. By product, HK inno.N's Kabalin’s sales amounted to ₩3 billion, Daewoong Bio's Lyribear amounted to ₩1.2 billion, Hanmi's Prebalin, and Gabaneuro amounted to ₩700 million, and Samjin's Neurocover-PG amounted to ₩600 million. The market's explosive growth didn’t reduce the popularity of generics for Lyrica. Domestic companies have obtained generic licenses until recently, three years after patent expiration. This year 17 pharmaceutical companies have received new approvals for 41 products. This accounts for 12% of the 338 generics. Quarterly share of Lyrica & generics (unit: ₩100 million, data:UBIST) Pfizer, the original company, came up with various strategies to prepare for competition with generic companies after Lyrica’s patent expiration. In February 2018, it was granted a low-dose product, and in July 2018, it was granted a sustained-release formulation in line with the patent expiration. However, it is observed that such a strategy is not very good yet. Only in the fourth quarter of last year, sustained-release formulation achieved only ₩100 million. In the third quarter of this year, only ₩160 million worth of prescriptions were prescribed.
- Company
- Rx performance is poor due to spin-off of Organon
- by Kim, Jin-Gu Nov 09, 2020 06:17am
- MSD Korea's spin-off of Organon has come for three months. However, sales of most Organon items, such as Singulair, Vitorin, and Cozaar, are sluggish in the domestic outpatient prescription market. In contrast, Sales of Januvia by MSD increased by nearly 10%. According to UBIST on the 4th, MSD's outpatient prescriptions in the third quarter of 2020 were ₩107.7 billion. Compared to ₩105.3 billion in the third quarter of last year, it increased by 2%. What is interesting is the change in prescription amount by item that MSD and Organon decided to share. The amount of prescriptions for major items in MSD increased, while the amount of prescriptions for items of Organon mostly decreased. First of all, Januvia prodcuts in MSD, increased prescriptions in the third quarter of this year compared to the third quarter of last year. MSD has a DPP-4 inhibitor-based diabetes treatment Januvia, Metformin combination drug Janumet, and Janumet XR. Januvia's prescription amount for the third quarter was ₩12.1 billion, a 5% increase from ₩11.5 billion a year earlier. During the same period, Janumet increased by 10% (₩11.8 billion → ₩20.6 billion and Janumet XR by 13% (₩11.5 billion → ₩13 billion). The total prescription amount for Januvia products increased 9% from ₩41.9 billion to ₩45.7 billion. The annual prescription amount for the three items was ₩168.2 billion last year, and this year's surpassed ₩170 billion is the most likely. Other products except Januvia will be transferred to Organon after spin-off. Among the products passed to Organon, Atozet is the only one with increased prescription performance. Changes in prescription amount for each major product of MSD in the third quarter (Unit: ₩100 million, Source: UBIST) On the other hand, it is observed that prescription sales of most of the items passed to Organon have decreased. The main items passed from MSD to Organon are ▲Atozet ▲Singulair ▲Vytorin ▲Cozaar ▲Fosamax and ▲Proscar. Among them, the remaining prescriptions except Atozet appeared to be decreasing or stagnating. Singulair, a treatment for asthma and allergic rhinitis, is the item with the largest decline. It decreased by 30% from ₩8.5 billion in the third quarter of last year to ₩5.9 billion in the third quarter of this year. It is an analysis that the US Food and Drug Administration (FDA) was affected by attaching a black box warning to the Montelukast formulation earlier this year. The domestic COVID-19 situation also contributed to the reduction of prescriptions. In the case of asthma and allergic rhinitis, the proportion of pediatric and adolescent patients is larger than that of other diseases, and since COVID-19 outbreak, visits to hospitals by pediatric and adolescent patients have decreased significantly. MSD's hypertension treatment Cozaar is still stagnant in prescription performance. MSD has five items in series: Cozaar, Cozaar XQ, Cozaar Plus, Cozaar Plus F, and Cozaar Plus-Pro. The total prescription amount for the five items in the third quarter of this year was ₩12.9 billion, down 1% from ₩13 billion in the third quarter of last year. Of the five, Cozaar and Cozaar Plus-Pro prescriptions increased, while Cozaar XQ, Cozaar Plus, and Cozaar Plus F decreased. Fosamax also decreased the amount of prescription. MSD has the osteoporosis treatments Fosamax, Fosamax Plus, and Fosamax Plus D. The total prescription for the three items in the third quarter was ₩3.9 billion, down 4% from ₩4.1 billion in the third quarter of last year. The prescription amount of Vytorin (Ezetimibe/Simvastatin), a hyperlipidemia combination drug, decreased 16% from ₩6 billion in the third quarter of last year to ₩5.1 billion in the third quarter of this year. Changes in prescription amount for each major item of MSD in 3Q (Unit: ₩100 million, Source: UBIST) Atozet (Ezetimibe/Atorvastatin), another combination of MSD's hyperlipidemia, is almost the only one that goes to Organon, where prescriptions have increased. Atozet's prescription amount increased 16% from ₩17 billion in the third quarter of last year to ₩19.7 billionin the third quarter of this year. MSD announced a spin-off plan at the global headquarters level earlier this year. The name of the spin-off company was decided as Organon. Organon focuses on patent expired medicines, women's health products, and biosimilars. Existing MSD focuses on blockbuster treatments, vaccines, and hospital-supplied medicines such as Lynparza, Lenvima, Gardasil, Bridion, Zerbaxa, and Bravecto, including Keytruda, an immune anticancer drug. However, Januvia is a drug that has expired, but it was decided to remain in MSD. MSD Korea is also undergoing a spin-off procedure. Last month, MSD Executive Director Kim So-eun was selected as the new CEO of Organon Korea. MSD Korea, which has reached its new head, is planning to announce a list of employees who will move to Organon by setting guidelines in November. MSD announced the completion of the spin-off in February next year. However, MSD Korea's labor union recently decided to engage in labor disputes in earnest, and as the domestic COVID-19 situation prolongs, there is a possibility that the spin-off operation may be disrupted. Business division plan that MSD released in February of this year (material Merck conference call)
- Company
- Servier Korea has appointed Melanie Loresry as new CEO
- by Eo, Yun-Ho Nov 06, 2020 06:25am
- Melanie Loresry, CEO of Servier Korea Servier Korea appoints a new head. According to related industries, Servier Korea appointed Melanie Loresry (43) as new CEO, on the 1st of last month. Colette Rouches, who had previously led Servier Korea, moved to a Taiwanese subsidiary. This allowed Servier to continue the female CEO system. French CEO Melanie Loresry has been in the pharmaceutical industry for about 20 years and has accumulated various experiences in pharmaceutical companies such as AstraZeneca and Novartis through sales, marketing, and medical departments. At Servier, she joined the French headquarters in 2017 and has served as Deputy Operational Manager in southern European countries such as Spain, Greece, Italy and Portugal. Meanwhile, Servier is a French pharmaceutical company with expertise in the field of cardiovascular disease, and supplies high blood pressure treatment 'Acertil' and heart failure treatment 'Procoralan' in Korea. In 2018, Servier acquired Shire's anticancer drug division, which was merged with Takeda, and secured the pancreatic cancer treatment 'Onivyde'. Onivyde was approved in Korea in 2017, but has not yet been listed on the insurance reimbursement list.
- Company
- MSD Korea’s trade union protests against organon's spinoff
- by Nov 06, 2020 06:25am
- Picket hung in front of MSD Korea headquarters The MSD Korea’s trade union began disputes on the 3rd due to the breakdown of the second round of mediation by the National Labor Relations Commission on the 2nd. On the 3rd, the union hung a picket and banner on the MSD Korea office building in Seoul Square, urging against the spin-off of Organon and urged cooperation in signing a collective agreement. As the spin-off of organon began in earnest, some members of the union executives held a demonstration for the first time since its formation on the morning of the 4th. The union also conveyed its intention to refuse the management meeting for the division of Organon. Earlier, union members in the DV/PC department to be moved signed a unilateral move to Organon. An official from the MSD Korea union said, "The union continuously raised issues about meetings that were held without the individual consent of the employees, but the management had only held formal meetings." He said that the meeting to communicate only the progress without collecting opinions from workers was judged to be meaningless, so we notified the company of the refusal to attend through the “struggle for the rights” twice. On the morning of the 4th, some of the union executives held a demonstration in front of Seoul Square for the first time since its formation
